Adenomyosis is a benign disease marked by the presence of ectopic endometrial glands and stroma which initiates reactive hypertrophy of the myometrium. This study rendered statistically significant difference in myometrial thickness pre- and post-MEA (Microwave endometrial ablation) which explored the usefulness of MEA and postoperative dienogest for treating uterine adenomyosis.

One of the major causes of menorrhagia and dysmenorrhea is uterine adenomyosis which reduces the women quality of life. One of the recently developed techniques that can allow endometrial ablation is the microwave endometrial ablation (MEA). Additionally, Dienogest employed to restrain endometrium growth and decrease adenomyosis-associated dysmenorrhea. Although, some patients can resist the Dienogest. This study assessed the effectiveness of a combination of MEA and postoperative Dienogest in reducing adenomyosis-related dysmenorrhea and menorrhagia.

A total of 10 participants with hormone treatment-resistant symptomatic adenomyosis went through MEA and delivered oral Dienogest following the procedure. The decrease in pain recurrence and anaemia were considered as the primary endpoints, and change in the adenomyosis lesion and its symptomatic recurrence were as secondary endpoints. 

Women showed statistically notable improvements in the haemoglobin levels and the visual analogue scale score postoperatively. A statistically meaningful difference was also seen in pre- and post MEA myometrial thickness. No incidence of symptomatic recurrence was found.

The MEA and postoperative Dienogest combination are beneficial for managing uterine adenomyosis with dysmenorrhea and menorrhagia.